Evaluation of NT‐Pro BNP and CT‐ANP as Markers of Concentric Hypertrophy in Dogs with a Model of Compensated Aortic Stenosis

Abstract

Background: Serum C-terminal atrial natriuretic peptide (CT-ANP) and N-terminal pro B-type natriuretic peptide (NT-pro BNP) concentrations have not been measured serially in dogs with chronic pressure overload of the heart. Hypothesis: We investigated whether serial evaluation of CT-ANP and NT-pro BNP concentrations is a useful guide to the risk of cardiac remodeling in dogs with a model of aortic stenosis.Animals: Six male Beagles. Methods: After anesthesia, the aorta was constricted with a polyester band and mean left ventricular systolic pressure (LVPs) was 50 mmHg above baseline. Echocardiographic and intracardiac catheter examinations and blood sampling were performed before surgery and 3 and 6 months after surgery.Results: LVP and left ventricular end-diastolic pressure (LVEDP) were significantly higher at 6 months. Compared with baseline, end-diastolic intraventricular septum thickness (IVSd), left ventricular posterior wall thickness (LVPWd), and relative wall thickness (RWT) were significantly increased 3 and 6 months after aortic constriction. Serum CT-ANP concentrations were increased significantly at 3 months and serum NT-pro BNP concentrations were significantly higher 3 and 6 months after aortic constriction. Serum NT-pro BNP concentration was significantly correlated with LVEDP and IVSd whereas serum CT-ANP concentration was not correlated with any measurement. Stepwise regression analysis showed that LVEDP, IVSd, and RWT could predict serum NT-pro BNP.Conclusions and Clinical Importance: This study indicated the differential regulation of NT-pro BNP and CT-ANP concentrations during pressure overload. NT-pro BNP assay may be used as an additional screening method to stratify early-stage ventricular remodeling because of aortic constriction.

NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs

“…NT-proBNP acted as a predictive biomarker of heart drug-induced liability as has been reported previously elsewhere (Panou et al 2006;Hori et al 2008). Moreover, these results provide evidence that NT-proBNP represents an excellent translational tool in assessing potential cardiotoxicity in preclinical studies during drug development.…”

“…As for humans, recent studies have shown that assessment of NT-proBNP concentration may be useful in identifying cardiac disease in dogs and grading disease severity Takemura et al 2009;Serres et al 2009;Piantedosi et al 2009;Moonarmart et al 2010). In a recent paper, the main role of NT-proBNP determination for the identification of early stage ventricular remodeling, secondary to aortic stenosis in dogs, was shown (Hori et al 2008). Authors were able to demonstrate a statistically significant correlation between NT-proBNP concentrations and left ventricular end-diastolic pressure and end-diastolic intraventricular septum thickness.…”

Therapeutic Changes of Plasma N-Terminal Pro-Brain Natriuretic Peptide Concentrations in 9 Dogs with Patent Ductus Arteriosus

“…Previous reports indicated reference values for the serum NT-proBNP concentration in normal dogs were 324 ± 119 pmol/L (mean value ± SD) [16] and 290 pmol/L (mean value) [22]. In addition, the NT-proBNP assay had adequate sensitivity and specificity for diagnosis of heart failure.…”

The evolution of the natriuretic peptides – Current applications in human and animal medicine

“…For example, in a pressure-overload model of aortic banding in 6 male Beagles, it was shown that NT-proBNP better correlated with left ventricular end diastolic pressures when compared to NT-proANP. 108 In addition, recent publications demonstrated that the diagnostic and prognostic value of NT-proBNP in cats and dogs was superior to NT-proANP. 109,110 In contrast to humans, 111 BNP and NT-proBNP concentrations in animals seem to be less associated with age or gender, while the associations with body weight and renal impairment have been found.…”